$71.78
-1.87-2.54%
Last update: Oct 30, 4:00 PM
Inhibrx Biosciences Inc (INBX) Stock Price, Quote, News & History
INBXNASDAQ
Inhibrx Biosciences reports Phase 2 HexAgon trial data showing improved response rates for INBRX-106 in head and neck cancer.
You can purchase shares of Inhibrx Biosciences (NASDAQ:INBX) through any online brokerage.
Other companies in Inhibrx Biosciences’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).
Inhibrx Biosciences has a consensus price target of $197.50.
The stock price for Inhibrx Biosciences (NASDAQ: INBX) is $71.78 last updated October 30, 2026 at 4:00 PM EDT.
There are no upcoming dividends for Inhibrx Biosciences.
Inhibrx Biosciences does not have any upcoming earnings scheduled.
There is no upcoming split for Inhibrx Biosciences.
Inhibrx Biosciences is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates...
